pozelimab show initi activ pnh
pozelimab show initi activ pnh phase studi patient reduc ldh
normal rang patient
think place market pozelimab though primarili limit
patient inelig ultomiri
initi activ shown place market unclear
expect regeneron share trade flattish today announc posit
top-line data pozelimab antibodi paroxysm nocturn
hemoglobinuria pnh posit program still question
product potenti competit given weekli dose schedul vs
ultomiri hesit switch among rare diseas patient overal
strength ultomiri clinic profil posit entrench standard care
still could place pozelimab treatment landscap among patient
variant resist alexion soliris/ultomiri ldh level pozelimab
patient compar favor seen ultomiri phase studi uln
vs uln howev hesit draw firm conclus given small sampl size
patient unclear baselin ldh level ultomiri baselin uln dont
consid pozelimab seriou threat ultomiri domin posit pnh
await derisk data give credit model current model
convers patient soliri ultomiri solidifi posit
standard care ahead new biosimilars/competitor entrant peak impact
model includ patient ultomiri resist mutat maintain
neutral rate rais po greater expect
earli pipelin asset includ pozelimab maintain buy rate po
phase data pozelimab one intraven load dose follow
subcutan weekli dose show improv lactat dehydrogenas
ldh biomark hemolysi level within normal rang week patient
achiev mean ldh level upper limit normal uln rang
uln higher hit rate ldh normal compar shown
phase studi ultomiri complement-inhibitor nave patient would caveat
data fact patient number small potenti variabl
baselin characterist safeti side advers event seriou led
discontinu treatment-rel report patient concern
headach inject site reaction nausea regeneron present data
phase pozelimab trial weekend alexion sever
present ultomiri planner initi thought
cohort phase trial patient on-going regeneron plan phase
trial compani note phase trial could potenti provid pivot data
howev given small patient number exist two approv treatment
pnh patient think phase trial like necessari
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
compon complement
uln upper limit normal
price object alexion base npv analysi
forecast sale approv product soliri ultomiri strensiq
kanuma well probabl adjust assum
wacc line peer compani similar size risk differ
termin valu asset depend specif characterist patent
protect given assumpt estim valu soliri
ultomiri strensiq kanuma net
cash round po
downsid risk success competitor trial price pressur less
expens treatment altern clinic trial failur
price object base probability-adjust net present valu npv
analysi eylea includ ou revenu bayer collabor
sanofi collabor revenu includ dupix product revenu
libtayo earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product
downsid risk price object slower-than-expect growth product
sale particularli eylea dupix failur obtain approv addit
indic dupix pipelin setback
upsid risk price object better expect eylea growth trajectori
larger contribut dupix regeneron top-line commerci uptak
new indic better expect econom realiz regeneron
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
bofa merril lynch current act financi advisor
inc connect propos acquisit achillion pharmaceut inc
announc octob propos transact subject approv
sharehold achillion pharmaceut inc research report intend
provid vote advic serv endors propos transact
result procur withhold revoc proxi
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current date one trade day prior date report
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current date one trade day prior date report
equiti invest rate distribut health group sep
equiti invest rate distribut global group sep
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
total return expect within period date initi rate
rate dispers guidelin coverag cluster
rate dispers may vari time time bofa merril lynch research believ better reflect invest prospect stock coverag cluster
incom rate indic potenti cash dividend same/high dividend consid secur same/low dividend consid secur pay
cash dividend coverag cluster compris stock cover singl analyst two analyst share common industri sector region classif stock
coverag cluster includ recent bofa merril lynch report referenc stock
price chart secur referenc research report avail http //pricechart baml com call mail
bofa one affili act market maker equiti secur recommend report
issuer within last month invest bank client bofa and/or one affili
bofa affili receiv compens issuer non-invest bank servic product within past month
issuer within last month non-secur busi client bofa and/or one affili
bofa affili receiv compens invest bank servic issuer within past month
bofa affili expect receiv intend seek compens invest bank servic issuer affili issuer within next three month alexion
bofa togeth affili benefici own one percent common stock issuer report issu day month reflect
ownership posit last day previou month report issu day month reflect ownership posit end second month preced date
report
bofa one affili will sell buy client common equiti issuer princip basi
issuer within last month secur busi client non-invest bank bofa and/or one affili regeneron
bofa merril lynch research personnel includ analyst respons report receiv compens base upon among factor overal profit america
corpor includ profit deriv invest bank analyst respons report may also receiv compens base upon among factor overal
profit bank sale trade busi relat class secur financi instrument analyst respons
